Study of Cyclin D1–targeted chemotherapy before oral cancer surgery
Part of Cancer, Mouth & dental clinical trials.
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old (male or female).
- Your health/ability to do daily activities is fair to good (Karnofsky score over 60).
- Your biopsy shows squamous cell cancer in the mouth area (such as tongue, gums, inner cheek, floor of mouth, palate, or behind the wisdom teeth).
- Your cancer test shows high Cyclin D1 levels.
- Your cancer stage is III or IVA and involves N2 lymph nodes, but there is no spread to distant organs (M0).
- Blood tests and organ function are adequate (enough white blood cells, hemoglobin, platelets, and acceptable liver/kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (Benmelstobart), a targeted therapy (Anlotinib), and standard chemotherapy given before surgery for advanced oral cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study helps doctors plan surgery more individually for early-stage oral (mouth) squamous cell carcinoma. It focuses on using tumor features found during evaluation to guide surgical decisions, aiming to improve treatment accuracy.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
Hear when a new Mouth Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.